Wells Fargo raised the firm’s price target on Argenx (ARGX) to $723 from $639 and keeps an Overweight rating on the shares. The firm adjusted price targets in the Smid-cap biotechnology group as part of its 2025 outlook. Wells top sector picks target Ascendis Pharma (ASND), aTyr Pharma (ATYR), Rhythm Pharmaceuticals (RYTM), and Xencor (XNCR).
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Argenx price target raised to EUR 740 from EUR 620 at JPMorgan
- Argenx price target raised to EUR 670 from EUR 650 at Barclays
- Argenx price target raised to $706 from $675 at Evercore ISI
- Argenx price target raised to $675 from $646 at Oppenheimer
- Argenx may have first targeted myositis treatment, says H.C. Wainwright